The FDA has finalized a rule that addresses how drug ads must be presented in TV and radio commercials. The rule, proposed in 2010 and now effective from May of this year, aims to provide clarity and guidelines for pharmaceutical companies in presenting side effects and contraindications in a balanced manner. But it’s still a 27-page document.

Here, we’ll boil it down for you.

Matthew Snodgrass, head of US Digital and Social Strategy at Syneos Health, sheds light on the 13-year journey from proposal to finalization, exploring key aspects of the rule, restrictions on distracting visuals during side effect discussions, and the use of quantitative terminology to convey information more precisely. The conversation delves into the challenges faced by regulatory teams in interpreting and implementing these rules and highlights the importance of understanding and following FDA guidelines in pharmaceutical advertising.

For a more detailed exploration of the FDA rule, check out our highlighted version of the full document in a downloadable PDF format. 

The views expressed in this podcast belong solely to the speakers and do not represent those of their organization.

If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health.

Like what you’re hearing? Be sure to rate and review us!

We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com.